Company Encyclopedia
View More
name
Oramed Pharma
ORMP.US
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc.
4.514 T
ORMP.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking84/184
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE24.38%A
    • Profit Margin2192.60%A
    • Gross Margin0.00%E
  • Growth ScoreB
    • Revenue YoY0.00%C
    • Net Profit YoY882.13%A
    • Total Assets YoY33.57%A
    • Net Assets YoY30.10%A
  • Cash ScoreC
    • Cash Flow Margin4.56%C
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.01E
  • Debt ScoreA
    • Gearing Ratio8.24%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    notice_summary_ytd.eps_title

    LB filings·
    US
    ORMP
    0.00%
    LB filings·
    US
    ORMP
    0.00%

    Oramed Pharmaceuticals reports $65 million net income for nine months ended September 2025

    Oramed Pharmaceuticals Inc. reported a pre-tax net income of $65 million for the nine months ended September 30, 2025, reversing a net loss of $6.1 million from the previous year. Basic earnings per share were $1.30, and diluted earnings per share were $1.26. Total assets increased by 42% year-over-year. The company also completed a $100 million principal repayment from Scilex and reported unrealized gains from equity holdings.

    Reuters·
    US
    ORMP
    0.00%
    Reuters·
    US
    ORMP
    0.00%

    Oramed Reports Fiscal Third Quarter 2025 Financial Results | ORMP Stock News

    Oramed Pharmaceuticals Inc. reported strong financial results for the nine months ending September 30, 2025, with a net income of $65 million, compared to a net loss of $6.1 million the previous year. The company's total assets increased by 42% to $220.5 million. Key drivers included a $100 million repayment from Scilex and unrealized gains from investments in Alpha Tau Medical Ltd. and others. CEO Nadav Kidron highlighted the success of their investment strategy and the company's enhanced financial flexibility for future opportunities.

    StockTitan·
    US
    ORMP
    0.00%
    StockTitan·
    US
    ORMP
    0.00%

    Oramed Pharmaceuticals Inc. announces stock purchase right dividend of one right per share with $10.00 exercise price

    Oramed Pharmaceuticals Inc. announced a dividend of one common stock purchase right per share, allowing shareholders to buy one share at $10.00 if conditions are met. No dividend was distributed last year. This announcement was made via PR Newswire on November 17, 2025.

    Reuters·
    US
    ORMP
    0.00%
    Reuters·
    US
    ORMP
    0.00%

    ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS | ORMP Stock News

    Oramed Pharmaceuticals Inc. announced a Rights Agreement and declared a dividend of one common stock purchase right per share. This plan aims to ensure fair treatment of stockholders in case of a hostile takeover. The rights become exercisable if a person or group acquires 15% or more of the company's stock. The distribution is set for November 27, 2025, and is not taxable to stockholders.

    StockTitan·
    US
    ORMP
    0.00%
    StockTitan·
    US
    ORMP
    0.00%
    © 2025 Longbridge｜Disclaimer